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This forum aims to review the current situation of
liver transplantation in HIV-infected patients. A few
years ago, the possibility of transplantation in HIV-
infected patients was considered an unrealizable dream.
Several major improvements have made this therapeutic
intervention possible. First, the advent of highly active
antiretroviral therapy (HAART) has dramatically mod-
iﬁed the prognosis of HIV-infected patients. Second, the
very eﬀective prophylaxis of HBV reinfection using a
combination of hyperimmune globulin anti-HBs and
nucleos/tide analogues after liver transplantation has
dramatically improved the prognosis of liver transplan-
tation in HBV-infected patients. Third, the greater
understanding of mechanisms involved in HCV recur-
rence after liver transplantation and the improvement
in antiviral therapy post-transplantation gives a reason-
ably optimistic view of the future of liver transplanta-0168-8278/$34.00  2008 European Association for the Study of the Liver.
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gh-turcott.tion in HCV-infected patients. Here, it is our aim to
explore new indications for this group of patients.2. How big is the problem? (R. Weber)
Worldwide, an estimated 33.2 million persons are
currently living with HIV infection including 15.4 mil-
lion women and 2.5 million children under 15 years
[1]. In 2007, 2.1 million adults and 0.4 million children
were newly infected, and 2.1 million died from HIV
infection. Globally, HIV infection is mostly transmitted
via heterosexual contacts, but intravenous drug use or
homosexual contacts contribute to HIV epidemiology
in some geographic areas. Regional statistics show enor-
mous diﬀerences in prevalence and incidence of HIV
infection. Only a minority of infected persons – 0.76 mil-
lion persons in Western and Central Europe and 1.3 mil-
lion in North America – are living in resource-rich
countries with unrestricted access to therapy. Based on
projections of economic and social development and
considering the historically observed relationships of
those with burden of disease, global HIV/AIDS-related
mortality is projected to possibly rise to 6.5 million in
2030. This model assumes coverage with antiretroviral
drugs will have reached 80% by 2012. Under optimistic
assumptions including increased prevention activities,
HIV/AIDS deaths are projected to increase to 3.7 mil-
lion in 2030 [2]. In higher income countries mortality
is expected to stabilize or to decrease during the next
decades, therefore, the burden of HIV-related diseases
and death will mainly aﬀect low-income countries.Published by Elsevier B.V. All rights reserved.
Table 1
Causes of liver disease in HIV-infected persons
Co-infections
 HIV-associated opportunistic infections (e.g., cytomegalovirus
infection, tuberculosis, non-tuberculous mycobacterial infections,
Bartonella henselae infection (peliosis hepatis)
 Tropical infections (e.g., visceral leishmaniasis, schistosomiasis)
Hepatotoxicity
 Antiretroviral drug-related toxicity
 Non-HIV medication-related toxicity
 Alcohol use
 Illegal drugs
Malignancies
 Hepatitis B and C virus-associated hepatocellular carcinoma
 HIV-associated malignancies (Non-Hodgkin’s lymphoma,
Kaposi’s sarcoma)
 Metastases of other malignancies
Metabolic
 Non-alcoholic steatosis hepatitis (NASH)
Immune-mediated
 Immune reconstitution inﬂammatory syndrome (IRIS) in hepatitis
virus co-infected persons
Non-HIV-related diseases
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pletely suppresses HIV-1 replication which results in res-
toration of cellular immune function, clinical
improvement, and a dramatic decrease of mortality
from 20–30 per 100 person-years before introduction
of potent drug regimens in 1995 to 1.5–2.5 per 100 per-
son-years in recent years [3]. Nevertheless, the risk of
death from AIDS is still substantial due to therapeutic
failure, late initiation of treatment, interruption or refu-
sal of treatment, incomplete adherence to therapy, or
drug resistance. Unfortunately, the search for a vaccine
has failed so far, and there is currently no reasonable
evidence that there will ever be one [4].
Hepatic opportunistic infections and malignancies
were found among 30–75% of patients with AIDS at
autopsy prior to the availability of antiretroviral ther-
apy, but liver disease rarely was the primary cause of
morbidity and rarely contributed to mortality. Such a
ﬁnding is still true in resource-poor countries without
treatment programs. HIV itself appears not to aﬀect
liver function and no ﬁndings speciﬁc or pathognomonic
for AIDS were identiﬁed in liver tissue. In contrast, in
patients with access to potent antiretroviral therapy,
deaths due to immunodeﬁciency-related complications
have decreased and an increasing proportion of deaths
are due to complications of liver diseases. Among 1246
deaths observed in the prospective D:A:D cohort study
between 1999 and 2004, liver-related death was even the
most frequent cause of non-AIDS-related deaths: 31.1%
of the patients died from AIDS, 14.5% due to liver-
related diseases, 11.0% from cardiovascular diseases,
9.4% from non-AIDS malignancies, and 33.8% from
other causes [3]. In this study, liver-related deaths were
a consequence of chronic hepatitis B (HBV) or hepatitis
C virus (HCV) co-infection in 76% of the patients. Inter-
estingly, there was a strong association between severity
of cellular immunodeﬁciency and risk of liver-related
death [3]. A total of 2.7% of deaths were reported to
be directly associated with antiretroviral medication.
Liver-related diseases among HIV-infected persons
are caused by HBV and HCV co-infections, hepatotoxic
medication, alcohol, illegal drugs, malignancies, meta-
bolic and immunologic mechanisms, and non-HIV-
related diseases (Table 1). Globally, an estimated 370
million persons are aﬀected by chronic HBV and 130
million by HCV infection [5]. Because HIV, HBV and
HCV share common routes of transmission, an esti-
mated 2–4 million HIV-infected persons are co-infected
with HBV and 4–5 million with HCV. The prevalence of
co-infections diﬀer by geographic region and by
patients’ demographic and behavioral characteristics.
The prevalence of chronic HBV infection is between
6–17% among HIV-infected persons living in HBV
endemic areas, and 4–17% among persons living in Eur-
ope or the USA depending on sexual or injection drug
use behavior. The prevalence of HCV co-infectionranges from 1–5% in persons who acquired HIV infec-
tion by heterosexual or homosexual contacts to 70–
95% in current or former injection drug users and trans-
fused hemophiliac patients. Thus, co-infections due to
HBV and HCV are the most frequent causes of liver dis-
ease in HIV infection and substantially contribute to
morbidity and mortality [5,6].
HCV and HIV infections adversely aﬀect each other:
HIV infection accelerates the progression of HCV dis-
ease by increasing hepatitis C viremia, causing cellular
immunodeﬁciency, increasing the risk of liver ﬁbrosis
and cirrhosis or leading to the rare ﬁbrosing cholestatic
hepatitis [7,8]. Vice versa, although debated [9], HCV
may adversely aﬀect the course of HIV infection [10],
reduces the eﬀectiveness of antiretroviral treatment,
and increases the rate of antiretroviral medication-
related hepatotoxicity [7,11]. Antiretroviral therapy has
been reported to reduce liver-related mortality in HCV
co-infected persons [12], but others did not ﬁnd such
an eﬀect [3]. Despite clinical and psychosocial obstacles
encountered in clinical practice, HCV treatment in HIV
co-infected persons is feasible with results similar to
those observed in randomized clinical trials. However,
many co-infected persons are not eligible for HCV treat-
ment due to somatic or psychosocial co-morbidities, and
contraindications for HCV drugs and those with decom-
pensated cirrhosis are not candidates for treatment [13].
HBV does not seem to enhance HIV progression or
aﬀect antiretroviral treatment response, but increases
liver-related mortality in co-infected persons [8]. HBV-
associated morbidity, however, is substantially reduced
among persons with access to care because nucleoside
and nucleotide reverse-transcriptase inhibitors used to
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long as treatment continues [14].
Adverse eﬀects of long-term antiretroviral treatment,
including mitochondrial toxicity, type 2 diabetes melli-
tus, cardiovascular diseases, and hepatotoxicity are
increasingly recognized [3]. Acute drug-induced liver
injury (DILI) related with some antiretroviral drugs is
unquestionable but an infrequent cause of severe mor-
bidity or mortality [15]. Acute hepatotoxicity is mainly
associated with the non-nucleoside reverse transcriptase
inhibitors and rarely with other drug classes. The prev-
alence of DILI of nevirapine and efavirenz containing
combination drug regimens is 3–15% and 1–4% of trea-
ted patients, respectively [16]. Whereas among the non-
HIV-infected population no association between HCV
infection and increased risk of DILI is known [17], such
toxicity is more frequently observed in HCV/HIV co-
infected compared with HIV monoinfected persons
[15,16]. Chronic hepatotoxicity of long-term antiretrovi-
ral therapy was not observed in randomized trials, usu-
ally lasting 12–24 months. However, two recent
observational studies found a 12% (95% conﬁdence
intervals, 4–20%) and 9% (2–16%) increase in liver-
related deaths per year of antiretroviral therapy, respec-
tively [3,18]. Furthermore, ‘‘cryptogenic” liver disease
has been described among approx. 0.5% of HIV-infected
persons without co-infections, alcohol use or other iden-
tiﬁable causes [19]. Observational data suggest that such
liver diseases may be associated with antiretroviral med-
ication. Recently, a novel histopathologic ﬁnding in the
HIV-infected population, named nodular regenerative
hyperplasia of the liver, has been documented in a series
of eight patients on antiretroviral therapy who presented
with symptomatic intrahepatic portal hypertension [20].
Although etiologically not proven at present, a relation-
ship with prolonged exposure to antiretroviral sub-
stances appears likely.
In conclusion, diseases leading to liver failure among
HIV-infected persons with access to care and antiretro-
viral therapy have become increasingly important as life
expectancy has lengthened. At present, up to 15% of
deaths among this patient group are due to liver dis-
eases. In addition to the burden of HCV, HBV co-infec-
tions, alcohol and illicit drug use, non-HIV medication-
related toxicity, as well as the metabolic syndrome con-
tribute to the heightened risk of liver injury.3. Criteria for selection of liver transplantation (P. Stock)
The acceptance criteria for liver transplantation in
HIV positive recipients continue to evolve with more
experience in the co-infected population. During the ini-
tial phases of liver transplantation in people with HIV,
selection criteria were justiﬁably conservative secondary
to logical concerns that providing further immunosup-pression to the HIV-positive recipient could result in
progression of HIV to AIDS. There were also ethical
concerns regarding the use of a scarce resource in a
group of recipients with unknown survival. However,
with good early results in many of the pilot trials, these
acceptance criteria have been gradually liberalized
[21–23].
During many of the initial clinical trials, solid organ
transplantation was limited to patients with an absolute
CD4+ T-cell count >200 cells/mL and controllable HIV
viremia on HAART therapy. These T-cell counts were
chosen as they were consistent with values that reﬂected
an intact immune system. However, many of the co-
infected patients with end-stage liver disease have portal
hypertension and massive splenomegaly, and an abso-
lute T-cell count <200/mL despite having well-con-
trolled HIV infection. The splenomegaly in these
patients could potentially result in splenic sequestration
of the T-lymphocytes, and contribute to the relatively
lower CD4+ counts noted in many of the co-infected
patients. For this reason, the T-cell requirement was
dropped to >100 cells/mL. Of note, absolute CD4+ T-
cell counts of >200 cells/mL are still required at the time
of kidney transplantation in the HIV-positive recipient.
There are some further caveats to the CD4+ T-cell
requirements for HIV-positive liver transplant recipi-
ents. In the US system for allocation of deceased donor
livers, allocation is based on the Model for End-Stage
Liver Disease (MELD) score. In addition, there can be
a signiﬁcant decrease in the absolute CD4+ T-cell count
in patients with decompensation of liver function and
increase of the MELD score. For this reason, the NIH
sponsored a US trial studying the safety and eﬃcacy
of solid organ transplantation in patients with an abso-
lute CD4+ T-cell count of >100 cells/mL within 3
months of transplantation. Another potential conﬂict
regarding the absolute requirement for a CD4+ count
>100 cells/mL relates to the use of interferon therapy
to treat HCV pre-transplant. The use of interferon can
cause a transient decrease in CD4+ T-cell counts, and
for this reason, the absolute CD4+ counts prior to the
initiation of interferon therapy should be taken into
account in the decision for liver transplantation. The
absolute CD4+ T-cell count is not relevant for children,
but rather the percentage of CD4+ T-lymphocytes that
matters. The percentage of CD4+ T-lymphocytes
should be greater than 30 for children between the ages
of 1–2 years, and greater than 20 for children between
the ages of 2–10.
An undetectable HIV viral load at the time of liver
transplantation is clearly a desirable goal for the surgical
team in the event of a needle stick. Unfortunately, many
liver transplant recipients are unable to tolerate
HAART therapy as a result of the signiﬁcant hepatotox-
icity. In the event that an undetectable HIV viral load is
not achievable as a result of drug-induced hepatotoxic-
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enced HIV clinician should predict the ability to control
the HIV virus post-transplant. This prediction is based
on a complete review of the antiretroviral history, HIV
RNA history, as well as resistance testing. Patients with
CD4+ counts <100/mL and multi-drug resistant HIV
should be excluded from transplantation. This issue is
more controversial for patients with CD4+ counts
>100/mL but detectable HIV that is multi-drug-resistant.
Most centers would still consider this as an exclusion
criteria, although with more data demonstrating the
safety of immunosuppression in the HIV-positive
patient as well as an increasing number of antiretroviral
agents, this exclusion criteria may be liberalized on a
case-by-case basis.
Another selection criterion for liver transplantation
that has been liberalized as a result of good early out-
comes was the initial exclusion of HIV-positive recipi-
ents that have had a history of an opportunistic
infection. However, following reconstitution of the
immune system with antiretroviral therapy, HIV posi-
tive liver transplant recipients are capable of mounting
an adequate immune response against most pathogens.
As a result, most centers are including patients following
reconstitution of the immune system with antiretroviral
therapy and appropriate antibiotic treatment. Nonethe-
less, opportunistic infections for which there is no reli-
able therapy should they recur post-transplant remain
an exclusion criteria. These infections include progres-
sive multifocal leukoencephalopathy (PML), chronic
cryptosporidiosis, and multi-drug resistant systemic fun-
gal infections. Patients with a history of AIDS-associ-
ated lymphoma are also excluded. Most clinical trials
include individuals with a history of resolved cutaneous
Kaposi’s sarcoma (KS). Recipients with this history
require a recent high-resolution CT scan without
evidence of pulmonary KS. Recent evidence that the
immunosuppressive agent sirolimus is eﬀective in the
treatment of KS may further expand the acceptance cri-
teria to include patients with a prior history of visceral
KS [24]. In fact, some transplants have been performed
in HIV-positive patients with a prior history of visceral
KS that has resolved following HAART-mediated
reconstitution of the immune system [25]. KS following
transplantation and immunosuppression has not been
problematic in the early clinical trials of solid organ
transplantation in people with HIV.
A ﬁnal area regarding selection of the HIV-positive
liver transplant recipient relates to the type of viral
co-infection (HBV versus HCV) aﬀecting the potential
recipient. To date, most centers performing transplants
in people with HIV have not altered selection criteria
based on the type of co-infection. However, initial trials
are consistently reporting signiﬁcantly better outcomes
in the HBV/HIV co-infected patients as compared to
the HCV/HIV co-infected patients. Despite the pres-ence of lamivudine-resistant HBV in the majority of
patients who have been on lamivudine therapy for
HIV management, the development of further resis-
tance to HBV has not been seen following transplanta-
tion and the administration of immunosuppression. In
fact, reports from the early clinical trials demonstrate
excellent patient and graft survival rates comparable
to the HIV-negative HBV-positive transplant recipients
[26]. Unfortunately, hepatitis C recurrence remains a
signiﬁcant problem in the HIV/HCV co-infected
patient following transplantation. Although HCV rein-
fection following liver transplantation is problematic in
all patients regardless of HIV status, it appears that
reinfection may be signiﬁcantly exacerbated in the co-
infected patient, resulting in poorer patient survival.
A recent report has identiﬁed high MELD scores at
the time of transplant to predict poor outcome in this
group of patients [27]. In this report, the ﬁve-year sur-
vival rates of the co-infected patients versus monoin-
fected patients was 51% and 81%, respectively.
Although the HIV/HCV co-infected cohorts have sig-
niﬁcantly poorer outcomes, there are also a number
of these recipients who have done well. Interestingly,
a few HIV/HCV co-infected patients have spontane-
ously cleared the HCV virus in the absence of inter-
feron therapy [28]. With more experience with liver
transplantation in the HIV/HCV co-infected group, it
may be possible to identify a cohort of patients that
will do better following transplantation. It may turn
out that transplantation in HIV/HCV co-infected
patients may have to be limited to patients with lower
MELD scores, higher body/mass indices, and absence
of renal insuﬃciency. Isolating the factors which have
resulted in poorer outcomes will lead to further reﬁne-
ment in the selection criteria for HIV/HCV co-infected
patients. Clearly, this reﬁnement will be dependent on
the eﬃcacy of newer therapies for the management of
hepatitis C recurrence following liver transplantation.4. Immunosuppression in HIV-infected patients: are any
special precautions necessary? (J.-C. Duclos-Valle´e)
In the current era of highly active antiretroviral ther-
apy (HAART), several reports have clearly demon-
strated that liver transplantation (LT) is feasible in
HIV-infected patients. Results have been excellent in
HIV/HBV co-infected patients, while in HIV/HCV co-
infected patients, outcomes have been satisfactory in
terms of survival beneﬁt because most patients had a
high MELD score [26,27,29,30]. We focus here on man-
aging the degree of immunosuppression before and after
liver transplantation in HIV-infected patients, with
goals of (1) not compromising survival after LT and
(2) improving the results of LT in the subgroup of
HIV/HCV co-infected patients.
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should be considered prior to liver transplantation?
Patients with uncontrolled HIV viral load secondary
to resistance to HAART should be excluded from LT,
not only because of the risk of transmission by needle
stick, but also because of the potential risk for septic
complications after liver transplantation.
With respect to the CD4+ cell count, it is currently
diﬃcult to deﬁne a CD4+ threshold that should exclude
patients from LT. In the ﬁrst 35 HIV/HCV co-infected
patients transplanted at Paul Brousse Hospital, all had
a CD4+ cell count >100 cells/mL which did not consti-
tute a factor likely to aﬀect post-LT survival. However,
although Ragni et al. noted that cumulative survival
among HIV-positive recipients was similar to that of
age- and race-comparable HIV-negative recipients, they
did observe poorer survival among patients with a
CD4+ cell count <200 cells/mL [21]. This factor should
be taken into account because the CD4+ cell count will
remain stable after LT but may decrease when pegylated
interferon therapy is administered for treatment of HCV
recurrence. Interestingly, in a recent series at Paul
Brousse Hospital, CD4+ cell counts <150 cells/mL were
observed in 7 patients, and 6 of these seven patients
developed severe chronic hepatitis C [27]. Clearly, the
impact of a low CD4+ cell count on the degree of sever-
ity of HCV recurrence needs to be demonstrated in a lar-
ger patient series [27].
Another important point to consider is how the
CD4+ cell count inﬂuences the survival of HIV/HCV
co-infected patients under HAART therapy; in fact, a
CD4+ cell gain of less than 100 cells/mL after starting
HAART was one of the most consistent factors associ-
ated with the emergence of severe hepatic events in a
recent study by Pineda et al. [31]. This low CD4+ level
was due in part to splanchnic sequestration secondary
to portal hypertension [32] and thus caused by
advanced ﬁbrosis, as has been shown in previous studies
[33]. A low CD4+ count could thus constitute a new
marker for liver disease severity in HIV/HCV co-
infected patients and be integrated in a speciﬁc MELD
score for HIV-infected patients prior to transplantation,
thus improving the prediction of survival of this
subgroup.
4.2. Should immunosuppression be managed speciﬁcally
following liver transplantation?
Apart from the study conducted by Schreibman et al.
[34], where HIV-infected patients experienced signiﬁ-
cantly higher mortality from infectious complications
(4 out of 15 transplanted patients), all the other reports
have reported a good control of HIV infection and
CD4+ cell counts with HAART after liver transplanta-
tion [21,26,27,29,30].The principal problem after liver transplantation in
HIV/HCV infected patients is the severity of HCV infec-
tion recurrence on the liver graft [27,29,30]. In the
monoinfected population, viral factors such as a high
viral load prior to LT, and host factors such as donor
age >50 years have been associated with a more severe
recurrence of HCV infection [35]. Moreover, an immu-
nosuppressed status is one of the most powerful deter-
minants of post-transplant disease progression as it
induces an increase in viral load [35]. Corticosteroid
boluses have been associated with a more severe course
of HCV recurrence and therefore should be avoided in
co-infected transplant patients. It is of course essential
to ensure a tailor-made immunosuppression in order
to control HCV recurrence and prevent acute rejection
in the subgroup of HIV/HCV co-infected patients.
Rapid corticosteroid withdrawal after LT should also
be avoided in co-infected patients, since it has been asso-
ciated with a more rapid ﬁbrosis progression in HCV-
monoinfected transplant recipients [36]. The data cur-
rently available have failed to reveal any consistent dif-
ferences in the incidence or severity of recurrent
hepatitis C between the two types of calcineurin inhibi-
tor (CNI) (tacrolimus or cyclosporine) in monoinfected
patients, thus it is too early to recommend either of these
immunosuppressant agents in HIV/HCV co-infected
patients [36]. It should also be noted that ﬁndings con-
cerning the eﬀects of other immunosuppressant agents
(such as MMF, anti-IL2 receptor antibodies, sirolimus
and azathioprine) on the severity of HCV recurrence
have so far been controversial in the HCV-monoinfected
population [35].
Because cyclosporine and tacrolimus are substrates of
cytochrome P-450 3A (CYP3A) and P-glycoprotein,
their elimination is inﬂuenced by the use of other drugs
that interact with these two enzymes, such as non-nucle-
oside reverse-transcriptase inhibitors (NNRTI) (which
are often CYP3A inducers) and protease inhibitors
(which are inhibitors of P-glycoprotein) [37]. To illus-
trate this type of interaction, recent studies have shown
that subjects receiving protease inhibitors (PI) and
cyclosporine had a 3-fold increase in AUC cyclosporine
levels, necessitating an 85% reduction in the cyclospor-
ine dosage over a two-year period (Table 2) [37]. As
for tacrolimus, when efavirenz or a nuclesoide analogue
combination was added, very little change in dosing was
required. By contrast, nelﬁnavir and particularly lopina-
vir/ritonavir have been shown to markedly inhibit the
ﬁrst pass metabolism of tacrolimus, resulting in an
increase in its elimination half-life and a reduction in
its oral clearance [38]. Overall, these results clearly dem-
onstrate that drug–drug interactions can be managed
through the careful monitoring of tacrolimus and cyclo-
sporine blood concentrations during the post-transplant
period, particularly when PIs are being administered
concomitantly [37].
Table 2
Eﬀects of antiretrovirals on immunosuppressants pharmacokinetics (from Teicher et al. [38], Frassetto et al. [52])
Cyclosporine Tacrolimus
NNRTIa (efavirenz) Higher doses No or little change
PIb Lower doses (4- to 5-fold) and increase
(50%) in dosing interval
Lower dose (75–93% decrease in the daily dose)
and increase in dosing interval (7-fold)
a NNRTI, non-nucleoside reverse transcriptase inhibitors.
b PI, protease inhibitors.
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tus prior to LT, and individualized management of
immunosuppressant therapy following LT are of crucial
importance in HIV-infected patients, and particularly
when trying to minimize the severity of HCV recurrence
in HIV/HCV co-infected patients. There is no doubt
that implementation of these recommendations will
improve the survival of HIV-infected patients following
LT in the very near future.5. Management before and after liver transplantation:
What do we know? (N. Terrault)
The published results show that liver transplantation
in HCV/HIV and HBV/HIV co-infected patients can be
successfully performed with overall short-term survival
rates [39] comparable to non-HIV- infected patients
[40]. Center-speciﬁc outcomes among liver transplant
recipients with HCV/HIV co-infection are variable with
some centers reporting lower survival in HCV/HIV
compared to HCV-monoinfected patients [27,30].6. Management of HBV and HCV before transplantation
There are several challenges in the management of
HIV-infected patients with HBV or HCV co-infection
requiring transplantation. The ﬁrst is to minimize deaths
on the waiting list. Late referral is one factor likely con-
tributing to deaths without transplantation [41,26].
However, a more rapid progression from ﬁrst decompen-
sation to death is frequent, particularly in HCV/HIV-
infected patients. In controlled studies, survival in
co-infected patients with decompensated cirrhosis was
signiﬁcantly shorter than in HIV-uninfected patients
[42]. The time from ﬁrst manifestation of liver decompen-
sation to death was 16 versus 48 months in co-infected
versus HCV-monoinfected patients [42] and predictors
of mortality after ﬁrst decompensation are age, severity
of liver disease (MELD and CPT scores) and the nature
of the decompensation event [42]. For HBV/HIV co-
infected patients, survival to the time of transplantation
is related to severity of disease at presentation and
whether uncontrolled drug-resistant HBV infection is
present [26,43]. Given the higher wait-list mortality in
HIV-infected patients, strategies to shorten waitingtimes, such as use of living donors or extended criteria
donors, are an important consideration. Additionally,
there may be a future need to consider MELD exemption
points to insure HIV-infected patients have comparable
wait-list mortality risk to HIV-uninfected patients.7. Management of HBV and HCV after transplantation
The other major challenge relates to the long-term
management of recurrent viral diseases, especially
HCV. Like HIV-uninfected transplant recipients, graft
and patient survival require prevention of reinfection or
control of progressive HBV and HCV diseases. For
HBV-infected patients, prophylactic therapies including
hepatitis B immunoglobulin and nucleos/tide analogues
are the cornerstone of management. For HCV-infected
patients, no prophylactic therapies are currently available
and the focus is on management of progressive disease
post-transplantation using pegylated interferon and riba-
virin. The safety and eﬃcacy of the therapies available to
manage these viral diseases are largely responsible for the
very diﬀerent outcomes in HBV/HIV co-infected patients
versus HCV/HIV co-infected patients.8. HBV/HIV co-infected liver transplant recipients
The goal of pre-transplant management in any HBV
patient is to have a low level of HBV DNA at the time of
transplantation to reduce the risk of HBV recurrence
post-transplantation. Additionally, sustained suppres-
sion of HBV DNA is associated with clinical improve-
ment and can obviate the need for liver
transplantation. Lamivudine resistance is common
among referred patients due to the frequent use of lam-
ivudine as part of HAART [26]. To prevent selection of
drug-resistant HBV in co-infected patients, experts rec-
ommend using combination therapy of tenofovir plus
emtricitabine or tenofovir plus lamivudine, as these
drugs are eﬀective against lamivudine-resistant and
wild-type HBV and also have anti-HIV activity [43].
These same drug combinations represent an excellent
antiviral strategy for liver transplant recipients with
and without lamivudine-resistant HBV.
The total number of transplant patients studied is
relatively small (N = 25) but results are uniform among
Table 3
Outcomes of HBV–HIV co-infected liver transplant recipients
Author, year, country N Patient survival
1 year (%)
HBV recurrence 1 year HBV prophylaxis used
Schreibman, 2007, US [34] 8 (2 with HCV) 75 11 HBIG for 1–12 months + long-term NAs
Roland, 2007, US [39] 5 100 0 HBIG + NAs indeﬁnitely
Duclos-Vallee, 2006, France [46] 5 100 – HBIG + NAs indeﬁnitely
Norris, 2006, UK [44] 4 100 0 HBIG + NAs indeﬁnitely
Fung, 2004, US [45] 3 (1 with HCV) 100 0 HBIG + NAs (duration unspeciﬁed)
HBIG: hepatitis B immune globulin; HBV: hepatitis B virus; HCV: hepatitis C virus; NA: nucleos/tide analogues.
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is 100% (range 75–100%), with no reported deaths
from recurrent HBV disease [34,39,44–46] (Table 3).
Longer-term survival data are lacking. All centers have
reported use of combination prophylaxis using HBIG
plus antivirals and HBV recurrence has been prevented
in the majority. Of note, among centers using indeﬁnite
HBIG plus antivirals, there have been no reports of
HBV recurrence, whereas in the one center using lim-
ited duration HBIG (1–12 months post-transplantation
only), recurrence at 1 year was 11% [44]. Since tenofo-
vir, lamivudine and emtricitabine are part of HAART,
interruptions in HAART due to intolerance or lack of
eﬃcacy requires consideration of the eﬀects of drug
interruption on HBV infection. In these situations, we
have used HBIG alone as prophylaxis when the dura-
tion of ART interruption is short-term. Alternatively
HBIG with an alternative HBV drug that does not
have HIV activity, such as adefovir or telbivudine,
could be used.
Prophylactic therapy should be continued life-long.
The detection of low level of HBV DNA in 53% of
HBV/HIV liver transplant recipients who were HBsAg
negative on combination prophylaxis [47] urges caution
in minimizing prophylactic therapies in these patients.
Indeed, provision of prophylaxis using therapies with
diﬀerent mechanisms of action such as combination
HBIG and nucleos/tide analogues would be predicted
to minimize risk of HBV recurrence long-term.Table 4
Survival HCV–HIV co-infected liver transplant recipientsa
Author, year, country N Patient survival
1 Year (%) 2 Year (
Norris, 2006, UK [44] 7 58 –
Castells, 2007, Italy [40] 9 – –
Neﬀ, 2003, US [22] 9 89 –
Vennarecci, 2006, Italy [49] 12b 83 58
Duclos-Vallee,2007, France[27] 35 – 73
de Vera 2007, USc[30] 27 67 –
Miro, 2008, Spain [51] 60 90 74
a Limited to studies reporting results on P5 transplant recipients.
b Survival for entire cohort of which 11/12 were HCV+.
c Some overlap of patients with Neﬀ, 2003, US [24].9. HCV/HIV co-infected liver transplant recipients
Survival at 1-year post-transplantation varies from
58% to 89% [48–51] (Table 4). The largest series from
Spain (N = 60) found patient survival rates of 90% at
1 year and 67% at 3 years [51]. Smaller series from Eur-
ope and the U.S. report 3-year survival rates of 56% to
88%. Two recently published studies comparing survival
in HCV/HIV co-infected and HCV-monoinfected trans-
plant recipients found a signiﬁcantly lower survival in
co-infected patients [27,30]. In a French study of 35
HCV/HIV-infected and 44 HCV-infected recipients, 2-
and 5-year patient survival rates were 73% vs. 91%
and 51% vs. 81%, respectively (p = 0.004) [27]. MELD
was the only signiﬁcant predictor of mortality, though
donor age was of borderline signiﬁcance (p = 0.06).
HIV infection per se did not predict survival. In a US
study of 27 HCV/HIV-infected and 41 HCV-infected
recipients, 3- and 5-year patient survival rates were
56% vs. 72% and 33% vs. 72%, respectively (p = 0.07)
[30]. Predictors of mortality were evaluated only in co-
infected patients and found to be African–American
race, pre-transplant MELD score >20, intolerance of
HAART post-transplant, and high post-transplant
HCV viral load [30].
The reason for the diﬀerences in survival among cen-
ters has not been systematically evaluated but may be
related to diﬀerences in severity of disease at the time
of transplantation, donor characteristics, or frequencyMortality attributed to
recurrent HCV (%)%) 3 Year (%) 5 Year (%)
– – 50
88 – –
– – –
58 – 27
– 51 38
56 33 37
67 – 54
Table 5
Eﬃcacy of HCV Therapy in HIV/HCV LT Recipients
Author N treated
genotypes
Peg and RBV doses Duration
(wks)
Biochemical
response
N (%)
SVR N (%) Histology stable
or improved
N (%)
Other ﬁndings
Wojcik, 2007,
German [48]
4, G1 (n = 2),
G2/3 (n = 2)
Peg-IFN 180 ug/wk
RBV 11/mg/kg
24–48 4/4 (100%) 4/4 (100%) 4/4 (100%) 2/4 with cholestatic
hepatitis
Castells, 2006,
Spain [50]
5, all G1 Peg-IFN 1.5 ug/kg
RBV 800–1000 mg/d
24–48 5/5 (100%) 1/5 (20%) N/A Rx started at ﬁrst
sign histologic
disease, median
12 wks
DeVera, 2006,
US [30]
15, majority G1 IFN and peg-IFN,
RBV 800 mg daily
54–131 10/15 (66%) 4/15 (27%) 1/9 (11%) 6 deaths during
treatment No
responses in those
with cholestatic
hepatitis
Duclos-Vallee,
2007, France [27]
19, G1 (n = 12) IFN and peg-IFN
and RBV
400–800 mg daily
Variable,
44–52 most
frequent
10/19 (53%) 3/19 (16%)
2/3 G3
3/19 (16%) 3 with severe
cholestatic disease;
2/3 treated,
1 death and 1
clinical response,
no SVRs
Vennarecci, 2006,
Italy [49]
9 Peg-IFN and RBV
(doses not provided)
N/A N/A 1/9 (11%) N/A 3 with severe
cholestatic hepatitis
Peg-IFN, pegylated interferon; RBV, ribavirin; SVR, sustained virologic response; G, genotype; N/A, not available in manuscript; Rx, treatment.
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tion and infections. Donor factors are of particular
importance as donor age is known to strongly inﬂuence
HCV disease severity in HCV-monoinfected patients
and there may be center-speciﬁc diﬀerences in the use
of extended-criteria donor in HCV/HIV-infected
patients. The incidence of acute rejection does not
appear to be increased in HCV/HIV co-infected patients
[27], but eﬀects of treated acute rejection on HCV dis-
ease progression may diﬀer in co-infected patients com-
pared to monoinfected patients. This has not been
studied.
Interactions between HAART drugs, speciﬁcally pro-
tease inhibitors (PIs) and non-nucleotide reverse trans-
criptase inhibitors such as efavirenz, and calcineurin
inhibitors and sirolimus are well-recognized [37,38]. In
addition to drug interactions, monitoring for HAART-
associated hepatotoxicity is important. Mitochondrial
toxicity related to nucleoside analogues has been
described with HAART. One study from France found
evidence of mitochondrial dysfunction in 5 patients with
severe recurrent HCV, with most cases developing while
patients were on DDI or D4T and in cases, with concur-
rent use of ribavirin [29]. Discerning HAART-related
hepatotoxicity on a background of recurrent HCV dis-
ease can be diﬃcult, if not impossible, so a high index
of suspicion is needed for patients with severe or unex-
pected deterioration in liver dysfunction.
Recurrent HCV disease is the single greatest chal-
lenge in the management of co-infected patients and
the leading cause of reduced survival. Recurrence of
HCV is nearly universal, though, quite remarkably,there are reports of spontaneous clearance of HCV
post-transplantation among co-infected patients [28].
Clinical evidence of recurrence appears earlier than in
HIV-uninfected HCV patients (median time 2 months).
Rate of ﬁbrosis progression is enhanced. In one con-
trolled study, the proportion with bridging ﬁbrosis or
cirrhosis at 2- and 5-year post-transplantation was
28% and 48% for HCV-HIV co-infected patients versus
10% and 18% in HCV-monoinfected patients [27]. The
proportion of graft losses speciﬁcally attributed to
recurrent disease is 27–54% with follow-up periods of
up to 5 years (Table 4). Cholestatic hepatitis, the most
severe form of recurrent HCV following transplanta-
tion, has been reported in most series of HCV/HIV
co-infected patients, though accurate incidence data
are lacking [27,40]. Prognosis for patients with this pre-
sentation appears poor but stabilization with antiviral
therapy has been reported [40].
Pegylated interferon and ribavirin combination ther-
apy is the mainstay for management of recurrent HCV
disease. Rates of sustained virologic response (SVR)
are predicted to be low in co-infected patients, given
the combined eﬀects of HIV infection and post-trans-
plant status on the eﬃcacy of treatment. Since SVR
rates are approximately 15% lower in co-infected than
monoinfected non-transplant HCV patients, and HCV-
infected transplant patients without HIV have SVR rates
at least 10% lower than non-transplant HCV- infected
persons, an SVR rate of 20–30% is predicted to the max-
imal achievable in co-infected transplant recipients.
Available data, with the exception of one outlier [50],
indicate a SVR is achievable in only 11–27% of treated
D. Samuel et al. / Journal of Hepatology 48 (2008) 697–707 705patients [27,30,48,50] (Table 5). Biochemical responses
on treatment are obtained in more than half of patients
but histological stabilization or improvement is rarely
seen in virologic non-responders (Table 5). Like HCV-
monoinfected transplant recipients, tolerability of full-
dose therapy is limited and likely contributes to the poor
SVR rates.
A myriad of unknowns regarding optimizing antiviral
therapy exist. Obviously, better tolerated and more eﬃ-
cacious drugs are needed. The optimal timing of treat-
ment needs to be determined. While tolerability of
treatment may limit early antiviral therapy, initiation
of treatment at the ﬁrst signs of histological disease
may be warranted to minimize risk of progression.
Whether a speciﬁc immunosuppressive regimen is better
suited to concurrent antiviral therapy is unknown. Cer-
tainly a stable immunosuppressive regimen is essential
prior to starting treatment to minimize risk of acute or
chronic rejection during antiviral treatment but beyond
this general adage, the optimal regimen is unclear.10. Conclusions and ‘‘What do we not know? (D. Samuel)
Short-term outcomes for HBV/HIV co-infected
patients are excellent. Prevention of HBV recurrence
can be achieved with combination HBIG and nucleos/
tide analogues. HIV disease does not appear to be
adversely aﬀected by transplantation, at least in the
short-term. Control of HBV replication prior to trans-
plantation is important to minimize the risk of recurrence
but a requirement for an undetectable HBV DNA level
may be too restrictive. Rather, the decision to transplant
patients with HBV/HIV infection with detectable HBV
DNA should be inﬂuenced by the level of HBV DNA,
the likelihood of achieving viral suppression with anti-
HBV agents (i.e. absence of a multidrug-resistant HBV)
and the availability of HBIG for prophylaxis. Studies in
HBV monoinfected patients indicate combination high-
dose HBIG and antivirals can eﬀectively prevent recur-
rence in viremic patients and this approach needs to be
tested in HBV/HIV co-infected patients also.
Outcomes for HCV/HIV co-infected patients are
more variable but poorer than HCV-monoinfected
patients and non-HCV-infected transplant recipients
[51]. With a 5-year survival of 50% or lower in most ser-
ies, there is clearly a need to examine critically the fac-
tors contributing to worse outcomes and adjust
practices accordingly. Divergent center-speciﬁc results
limit interpretation of results, but one predictor of
reduced survival is consistently seen. Patients with high
MELD scores do poorly. This emphasizes the need to
develop strategies to get these patients to transplanta-
tion earlier. Optimization of donor (age, steatosis) and
perioperative factors (cold ischemia time) may also
reduce the severity of HCV recurrence and since recur-rent HCV disease is a leading cause of graft loss, factors
known to inﬂuence disease progression in HCV-mono-
infected patients need to be considered in patient man-
agement. Clearly an absence of eﬀective antivirals is
the major limitation. Additional agents, speciﬁcally pro-
tease and polymerase inhibitors with activity against
HCV, will be predicted to signiﬁcantly aﬀect the out-
comes of HCV/HIV transplant recipients. Until such
drugs are available, however, alternative treatment par-
adigms need to be examined including pre-transplant
therapy, preemptive therapy, (early and prior to histo-
logic recurrence) or maintenance therapy.
In conclusion, this overview shows that excellent
results of liver transplantation in HIV/HBV co-infected
patients can be achieved. It shows as well that liver
transplantation in HIV/HCV co-infected patients
remains diﬃcult. However, improvements in this latter
setting are in process. In order to improve the results,
a better selection of candidates for liver transplantation
at an earlier stage of their liver disease will be needed, as
well as an accurate scoring of severity of liver disease in
HIV-infected patients, and an accessibility to liver trans-
plantation taking into account the severity of liver dis-
ease through MELD score or modiﬁed MELD score.
Better management of HAART after transplantation
and a more eﬀective antiviral therapy against HCV are
also required.
References
[1] UNAIDS/WHO. AIDS epidemic update: December 2007. Gene-
va, Switzerland: Joint United Nations Programme on HIV/AIDS
and World Health Organization, 2007.
[2] Mathers CD, Loncar D. Projections of global mortality and
burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
[3] Weber R, Sabin CA, Friis-Moller N, Reis P, El-Sadr WM, Kirk
O, et al. Liver-related deaths in persons infected with the human
immunodeﬁciency virus: the D:A:D study. Arch Int Med
2006;166:1632–1641.
[4] Steinbrook R. One step forward, two steps back – will there ever
be an AIDS vaccine? N Engl J Med 2007;357:2653–2655.
[5] Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J
Hepatol 2006;44:S6–S9.
[6] Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J
Med 2007;356:1445–1454.
[7] Vallet-Pichard A, Pol S. Natural history and predictors of severity
of chronic hepatitis C virus (HCV) and human immunodeﬁciency
virus (HIV) co-infection. J Hepatol 2006;44:S28–S34.
[8] Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu` G,
et al. Short statement of the ﬁrst European consensus conference
on the treatment of chronic hepatitis B and C in HIV co-infected
patients. J Hepatol 2005;42:615–624.
[9] Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH,
Horban A, et al. Inﬂuence of hepatitis C virus infection on HIV-1
disease progression and response to highly active antiretroviral
therapy. J Infect Dis 2005;192:992–1002.
[10] Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer
H, et al. Clinical progression, survival, and immune recovery
during antiretroviral therapy in patients with HIV-1 and hepatitis
C virus coinfection: the Swiss HIV cohort study. Lancet
2000;356:1800–1805.
706 D. Samuel et al. / Journal of Hepatology 48 (2008) 697–707[11] den Brinker M, Wit FW, Wertheim-van Dillen PM, Juriaans S,
Weel J, Van Leeuven R, et al. Hepatitis B and C virus co-infection
and the risk for hepatotoxicity of highly active antiretroviral
therapy in HIV-1 infection. Aids 2000;14:2895–2902.
[12] Qurishi N, Kreuzberg C, Luchters G, Lu¨chters G, Eﬀenberger W,
Kupfer B, et al. Eﬀect of antiretroviral therapy on liver-related
mortality in patients with HIV and hepatitis C virus coinfection.
Lancet 2003;362:1708–1713.
[13] Zinkernagel AS, von Wyl V, Ledergerber B, Rickenbach M,
Furrer H, Battegay M, et al. Eligibility for and outcome of
hepatitis C treatment of HIV-coinfected individuals in clinical
practice: the Swiss HIV cohort study. Antivir Ther
2006;11:131–142.
[14] Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus-
HIV-coinfected patients: promises and pitfalls. Clin Infect Dis
2006;43:904–910.
[15] Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepato-
toxicity associated with antiretroviral therapy in adults infected
with human immunodeﬁciency virus and the role of hepatitis C or
B virus infection. JAMA 2000;283:74–80.
[16] Nunez M. Hepatotoxicity of antiretrovirals: incidence, mecha-
nisms and management. J Hepatol 2006;44:S132–S139.
[17] Schenker S, Martin RR, Hoyumpa AM. Antecedent liver disease
and drug toxicity. J Hepatol 1999;31:1098–1105.
[18] Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, De Wit S,
et al. Is there evidence for an increase in the death rate from liver-
related disease in patients with HIV? Aids 2005;19:2117–2125.
[19] Maida I, Nunez M, Rios MJ, Martin-Carbonero L, Sotgiu G,
Toro C, et al. Severe liver disease associated with prolonged
exposure to antiretroviral drugs. J Acquir Immune Deﬁc Syndr
2006;42:177–182.
[20] Mallet V, Blanchard P, Verkarre V, Vallet-Pichard A, Fontaine H,
Lascoux-Combe C, et al. Nodular regenerative hyperplasia is a
new cause of chronic liver disease in HIV-infected patients. Aids
2007;21:187–192.
[21] Ragni MV, Belle SH, Im K, Neﬀ G, Roland M, Stock P, et al.
Survival of human immunodeﬁciency virus-infected liver trans-
plant recipients. J Infect Dis 2003;188:1412–1420.
[22] Neﬀ GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiﬀ
ER, et al. Orthotopic liver transplantation in patients with human
immunodeﬁciency virus and end-stage liver disease. Liver Transpl
2003;9:239–247.
[23] Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose
R, et al. Kidney and liver transplantation in human immunode-
ﬁciency virus-infected patients: a pilot safety and eﬃcacy study.
Transplantation 2003;76:370–375.
[24] Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio
G, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant
recipients. N Engl J Med 2005;352:1317–1323.
[25] Calabrese LH, Albrecht M, Young J, McCarthy P, Haug P,
Jarcho J, et al. Successful cardiac transplantation in an HIV-1-
infected patient with advanced disease. N Engl J Med
2003;348:2323–2328.
[26] Terrault NA, Carter JT, Carlson L, Roland ME, Stock PG.
Outcome of patients with hepatitis B virus and human immuno-
deﬁciency virus infections referred for liver transplantation. Liver
Transpl 2006;12:801–807.
[27] Duclos-Vallee JC, Feray C, Sebagh M, Teicher E, Roque-Afonso
AM,RocheB, et al. Survival and recurrence of hepatitisC after liver
transplantation in patients coinfected with human immunodeﬁ-
ciency virus and hepatitis C virus. Hepatology 2008;47:407–417.
[28] Bhagat V, Foont JA, Schiﬀ ER, Regev A. Spontaneous clearance
of hepatitis C virus after liver transplantation in two patients
coinfected with hepatitis C virus and human immunodeﬁciency
virus. Liver Transpl 2008;14:92.
[29] Duclos-Valle´e JC, Vittecoq D, Teicher E, Feray C, Roque-Afonso
AM, Lombes A, et al. HCV viral recurrence and liver mitochon-drial damage after liver transplantation in HIV–HCV coinfected
patients. J Hepatol 2005;42:341–349.
[30] De Vera ME, Dvorchik I, Tom K, Eghtesad B, Thai N, Shakil O,
et al. Survival of liver transplant patients coinfected with HIV and
HCV is adversely impacted by recurrent hepatitis C. Am J Transpl
2006;6:2983–2993.
[31] Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M, Rios-Villegas
MJ, Ruiz-Morales J, Rivero A, et al. Clinical progression of
hepatitis C virus-related chronic liver disease in human immuno-
deﬁciency virus-infected patients undergoing highly active anti-
retroviral therapy. Hepatology 2007;46:622–630.
[32] McGovern B, Golan Y, Lopez M, Pratt D, Lawton A, Moore G,
et al. The impact of cirrhosis on CD4 T cell counts in HIV-
seronegative patients. Clin Infect Dis 2007;44:431–437.
[33] Benhamou Y, Di Martino V, Bochet M, Colombet C, Thibault V,
Liou M, et al. Factors aﬀecting liver ﬁbrosis in human immuno-
deﬁciency virus-and-hepatitis C virus-coinfected patients: impact
of protease inhibitor therapy. Hepatology 2001;34:283–287.
[34] Schreibman I, Gaynor JJ, Jayaweera D, Pyrsopoulos N, Weppler
D, Tzakis A, et al. Outcomes after orthotopic liver transplantation
in 15 HIV-infected patients. Transplantation 2007;84:697–705.
[35] Roche B, Samuel D. Risk factors for hepatitis C recurrence after
liver transplantation. J Viral Hep 2007;14:89–96.
[36] Berenguer M, Royuela A, Zamora J. Immunosuppression with
calcineurin inhibitors with respect to the outcome of HCV
recurrence after liver transplantation: results of a meta-analysis.
Liver Transpl 2007;13:21–29.
[37] Frassetto L, Baluom M, Jacobsen W, Christians U, Roland ME,
Stock PG, et al. Cyclosporine pharmacokinetics and dosing
modiﬁcations in human immunodeﬁciency virus-infected liver and
kidney transplant recipients. Transplantation 2005;80:13–17.
[38] Teicher E, Vincent I, Bonhomme-Faivre L, Abbara C, Barrail A,
Boissonnas A, et al. Eﬀect of highly active antiretroviral therapy
on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-
infected liver transplant recipients in the ANRS HC-08 study. Clin
Pharmacokinet 2007;46:941–952.
[39] Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA,
Hirose R, et al. HIV-infected liver and kidney transplant recipients:
1- and 3-Year Outcomes. Am J Transplant 2008;8:355–365.
[40] Castells L, Escartin A, Bilbao I, Len O, Allende H, Vargas V,
et al. Liver transplantation in HIV–HCV coinfected patients: a
case-control study. Transplantation 2007;83:354–358.
[41] Ragni MV, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ.
Pretransplant survival is shorter in HIV-positive than HIV-
negative subjects with end-stage liver disease. Liver Transpl
2005;11:1425–1430.
[42] Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez
JA, Montero JL, Torre-Cisneros J, et al. HIV coinfection shortens
the survival of patients with hepatitis C virus-related decompen-
sated cirrhosis. Hepatology 2005;41:779–789.
[43] Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh
J, et al. Care of patients with chronic hepatitis B and HIV co-
infection: recommendations from an HIV–HBV International
Panel. Aids 2005;19:221–240.
[44] Norris S, Taylor C, Muiesan P, Portmann BC, Knisely AS,
Bowles M, et al. Outcomes of liver transplantation in HIV-
infected individuals: the impact of HCV and HBV infection. Liver
Transpl 2004;10:1271–1278.
[45] Fung J, Eghtesad B, Patel-Tom K, DeVera M, Chapman H,
Ragni M. Liver transplantation in patients with HIV infection.
Liver Transpl 2004;10:S39–S53.
[46] Duclos-Vallee JC, Feray C, Sebagh M, Teicher E, Roque-Afonso
AM, Roche B, et al. Liver transplantation of HIV–HCV and
HIV–HBV coinfected patients:A large experience in a single
centre. J Hepatol 2006;44:S8.
[47] Coﬃn C, Berg C, Dove L, Poordad F, Curry M, Regenstein F,
et al. Survival and risk of hepatitis B virus recurrence in HIV–
D. Samuel et al. / Journal of Hepatology 48 (2008) 697–707 707HBV coinfected liver transplant recipients: interim ﬁndings from
the HIV–TR study. Hepatology 2007;46:245A.
[48] Wojcik K, Vogel M, Voigt E, Speidel N, Kalﬀ JC, Goldmann G,
et al. Antiviral therapy for hepatitis C virus recurrence after liver
transplantation in HIV-infected patients: outcome in the Bonn
cohort. Aids 2007;21:1363–1365.
[49] Vennarecci G, Ettorre GM, Antonini M, Santoro R, Perracchio
L, Visco G, et al. Liver transplantation in HIV-positive patients.
Transplant Proc 2007;39:1936–1938.
[50] Castells L, Esteban JI, Bilbao I, Vargas V, Allende H, Ribera E,
et al. Early antiviral treatment of hepatitis C virus recurrence afterliver transplantation in HIV-infected patients. Antivir Ther
2006;11:1061–1070.
[51] Miro´ J, Montejo M, Castells L, Rafecas A, Salcedo M, Fortu´n J,
et al. Prognostic Factors of Mortality in HCV/HIV Coinfected
Liver Transplant Recipients From the FIPSE OLT-HIV-05 -
GESIDA 45-05 Cohort Study (2002-06). 15th CROI Meeting,
Boston, MA, 2008, p. 177.
[52] Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME,
Stock PG, et al. Immunosuppressant pharmacokinetics and
dosing modiﬁcations in HIV-1 infected liver and kidney transplant
recipients. Am J Transplant 2007;7:2816–2820.
